Current Treatments
BETASERON® (interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis

AVONEX® (Interferon beta-1a) is a 166 amino acid glycoprotein with a predicted molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of AVONEX® is identical to that of natural human interferon beta.

COPAXONE is the brand name for glatiramer acetate (formerly known as copolymer-1). Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000 – 9,000 daltons. Glatiramer acetate is identified by specific antibodies.

Rebif® (interferon beta-1a) is a purified 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of Rebif® is identical to that of natural fibroblast derived human interferon beta. Natural interferon beta and interferon beta-1a (Rebif®) are glycosylated with each containing a single N-linked complex carbohydrate moiety.

Tysabri is a monoclonal antibody that affects the actions of the body's immune system. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Tysabri is used to treat relapsing forms of multiple sclerosis.
Gilenya™ is a new class of medication called a phingosine 1-phosphate receptormodulator, which is thought to act by retaining certain white blood cells (lympohcytes) in the lymph nodes, thereby preventing those cells from crossing the blood-brain barrier into the central nervous system (CNS). Preventing the entry of these cells into the CNS reduces inflammatory damage to nerve cells.


Early Symptoms
The most common early symptoms of MS include:
* Tingling * Numbness
* Loss of balance
* Weakness in one or more limbs
* Blurred or double vision

Less common symptoms of MS may include
* Slurred speech
* Sudden onset of paralysis
* Lack of coordination
* Cognitive difficulties
Listed above, the early symptoms. I tend to be a poster child for these. The symptoms that occur later on are too numerous just to list. There will be a link included that will get you to a site where these symptoms are listed and explained. Keep in mind that someone may have some of these or many of these, there is no way to tell.
Multiple sclerosis statistics show that approximately 250,000 to 350,000 people in the United States have been diagnosed with this disease. The life expectancy for people with multiple sclerosis is nearly the same as for those without MS. Because of this, multiple sclerosis statistics place the annual cost of MS in the United States in the billions of dollars. MS is five times more prevalent in temperate climates -- such as those found in the northern United States, Canada, and Europe -- than in tropical regions. Furthermore, the age of 15 seems to be significant in terms of risk for developing the disease. Some studies indicate that a person moving from a high-risk (temperate) to a low-risk (tropical) area before the age of 15 tends to adopt the risk (in this case, low) of the new area and vice versa. Other studies suggest that people moving after age 15 maintain the risk of the area where they grew up.

Friday, December 2, 2011

Federal Focus - December 2011

The National MS Society is incredibly grateful to our strong and bold network of over 64,000 MS activists across the country who advocate year-round for policies that will improve the lives of people living with MS. We wish everyone a very happy holiday season and look forward to continuing to work together next year!

Society Submits Recommendations as Funding Levels are Finalized
Each year, Congress is tasked with passing the federal budget that funds federal departments, agencies, and programs. Through the federal budget cycle, funding levels for agencies and programs important to people living with MS like Medicare, Medicaid, Social Security, and the National Institutes of Health are decided—which in turn, impact access to health and other services like respite care and the amount of funding available for MS research. This complex process is supposed to be completed each year by the start of the fiscal year—October 1—but in the recent past, has not been. Congress has instead passed what is known as a “Continuing Resolution” (CR) that maintains or "flat funds" programs to give Congress more time to complete appropriations.

The federal government is currently operating under one of these CRs that is in place through December 16. Over the next few weeks, Congress will be deciding whether to wrap remaining appropriations bills into a large package called an “omnibus” or pass another CR. Whichever path is selected, to help ensure that programs and services for people with MS receive adequate funding, the Society is sending a letter to Congressional leadership and appropriators to recommend robust levels for the following: MS research in the Congressionally Directed Medical Research Programs (CDMRP), the National Institutes of Health (NIH), a new program aimed at expediting development of effective drugs called the Cures Acceleration Network (CAN), the Lifespan Respite Care Program that supports family caregivers, and the Social Security Administration. Funding for another Society priority—the Food and Drug Administration—has already been finalized and fortunately received a $50 million increase over last year’s level.

With Fade-Out of the Super Committee, Across-the-Board Cuts Expected
As part of the agreement to raise the debt ceiling this past summer, Congress created the Joint Select Committee on Deficit Reduction, otherwise known as the ‘Super Committee.’ It was tasked with identifying $1.2 trillion in budget savings over the next ten years. The committee had a hard deadline of November 23 to bring forward a proposal but on November 22 the co-chairs announced they were unable to come to an agreement. Now all the focus is on what happens next.

Under the law, there will be automatic across-the-board cuts, known as sequestration, beginning January 1, 2013, to meet the $1.2 trillion over ten years target--with half of the cuts coming from defense spending and half from non-defense spending. Medicaid, Social Security, and Medicare beneficiaries are exempt from these cuts but it is possible that cuts to administrative costs within those programs could make things like SSDI submissions longer to approve. The cuts impacting Medicare will hit the providers – they face up to a 2% reduction annually. Other areas of the budget important to people living with MS, like the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Centers for Disease Control (CDC) could face significant cuts. The Congressionally Directed Medical Research Programs (CDMRP)--which fund high risk, high reward research including research into MS--may also be hit.

Congress could pass another law to alter the sequestration, or cancel it altogether, but President Obama has taken a hard-line stating that he would veto any effort to alter the Budget Control Act and the automatic cuts. The Obama Administration is likely hopeful that such a stance will get Congress back to the negotiating table to come up with a workable plan to achieve at least $1.2 trillion in savings. For more details on how sequestration will work, we urge you to read this

No comments:

About Me

My photo
North Grafton, Massachusetts, United States
Well-educated, disabled at this point with Multiple Sclerosis. I am very glad that I was able to do the things that I have been able to do over the years. had to change the picture, this one's more realistic.